🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

514 results for “Vir” Clear

  1. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis Pharmaceuticals

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  2. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Pharmaceuticals

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  3. ACICLOVIR VIATRIS 500 mg, poudre pour solution injectable (I.V.), CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  4. ASC09F+Oseltamivir

    Tongji Hospital

    2019-nCoV Pneumonia

    phase 3 small molecule active

    1 trial

  5. Acyclovir

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  6. Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)

    Seqirus (Australia) Pty Ltd

    Influenza Virus

    phase 3 mab completed

    1 trial

  7. Aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer

    phase 3 mab active

    1 trial

  8. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  9. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  10. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  11. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  12. Azithromycin plus hydroxychloroquine

    Iterum Therapeutics plc

    Respiratory Tract Infection Viral

    phase 3 small molecule terminated

    1 trial

  13. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  14. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  15. Baloxavir Marboxil

    Hoffmann-La Roche

    Influenza

    phase 3 small molecule completed

    1 trial

  16. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial

  17. Bemnifosbuvir (BEM)

    Atea Pharmaceuticals

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

    phase 3 small molecule completed

    1 trial

  18. Bemnifosbuvir-Ruzasvir

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  19. Bemnifosbuvir-Ruzasvir (BEM/RZR)

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  20. Bemnifosbuvir/Ruzasvir Fixed Dose Combination (FDC), Sofosbuvir / Velpatasvir

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus (HCV) Infection

    phase 3 small molecule active

    1 trial

  21. Bepirovirsen

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

  22. Beyfortus 100 mg solution for injection in pre-filled syringe, Beyfortus 50 mg solution for injection in pre-filled syringe, Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)

    Fondazione Telethon ETS

    Respiratory Syncytial Virus (RSV)

    phase 3 small molecule active

    1 trial

  23. Bictegravir

    Gilead Sciences Ireland UC

    HIV-1-infection

    phase 3 small molecule active

    2 trials

  24. Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM ISL/LEN, ISLATRAVIR/LENACAPAVIR, ISLATRAVIR/LENACAPAVIR, PTM Biktarvy

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources